RxDoctor Payments Data

Barry Brook, MD

Internal Medicine · Cincinnati, OHNPI 1215993779

Payments from drug & device makers

$11,368in general payments, 2019–2025

Across 718 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • GSK$689
  • Abbott$656
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$11,23099%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,368 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$167,506
Medicare patients
447
Services billed
1,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$177,176
FarxigaDapagliflozin Propanediol102$84,602
OzempicSemaglutide48$53,000
TrulicityDulaglutide30$34,570
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$32,140
XareltoRivaroxaban35$31,167
JardianceEmpagliflozin22$29,209
MounjaroTirzepatide18$19,667
JanuviaSitagliptin Phosphate13$17,955
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$16,775
LinzessLinaclotide28$14,089
JanumetSitagliptin Phos/Metformin Hcl15$11,731
Tresiba Flextouch U-200Insulin Degludec15$9,889
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$9,761
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$8,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,182$178,543268 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,504$107,133150 claims
Lilly USA, LLCTrulicity, Mounjaro$388$54,23748 claims
Novo NordiskOzempic$1,020$53,00048 claims
Boehringer IngelheimJardiance, Combivent Respimat$287$35,24734 claims
GSKTrelegy Ellipta$689$32,14029 claims
Johnson & JohnsonXarelto$471$31,16735 claims
MerckJanuvia, Janumet$347$29,68528 claims
AbbVieLinzess, Synthroid$1,419$17,20394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →